Shantha Biotech Of India Entertains GSK As New Suitor
This article was originally published in PharmAsia News
Executive Summary
India's Shantha Biotech has attracted another suitor, this time GlaxoSmithKline. GSK seeks a 51 percent stake in Shantha, whose recent negotiations with Sanofi Aventis for a similar deal fell apart. The shares GSK seeks are some of those owned by Merieux Alliance of France. Merieux bought a 60 percent stake in Shantha in 2006 and added another 20 percent recently. GSK seeks Shantha's vaccine business. (Click here for more